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Abstract
Background: Chronic Chagas cardiomyopathy (CCC), a life-threatening inflammatory dilated cardiomyopathy, affects 30%
of the approximately 8 million patients infected by Trypanosoma cruzi. Even though the Th1 T cell-rich myocarditis plays a
pivotal role in CCC pathogenesis, little is known about the factors controlling inflammatory cell migration to CCC
myocardium.
Methods and Results: Using confocal immunofluorescence and quantitative PCR, we studied cell surface staining and gene
expression of the CXCR3, CCR4, CCR5, CCR7, CCR8 receptors and their chemokine ligands in myocardial samples from end-
stage CCC patients. CCR5+, CXCR3+, CCR4+, CCL5+ and CXCL9+ mononuclear cells were observed in CCC myocardium.
mRNA expression of the chemokines CCL5, CXCL9, CXCL10, CCL17, CCL19 and their receptors was upregulated in CCC
myocardium. CXCL9 mRNA expression directly correlated with the intensity of myocarditis, as well as with mRNA expression
of CXCR3, CCR4, CCR5, CCR7, CCR8 and their ligands. We also analyzed single-nucleotide polymorphisms for genes
encoding the most highly expressed chemokines and receptors in a cohort of Chagas disease patients. CCC patients with
ventricular dysfunction displayed reduced genotypic frequencies of CXCL9 rs10336 CC, CXCL10 rs3921 GG, and increased
CCR5 rs1799988CC as compared to those without dysfunction. Significantly, myocardial samples from CCC patients carrying
the CXCL9/CXCL10 genotypes associated to a lower risk displayed a 2–6 fold reduction in mRNA expression of CXCL9,
CXCL10, and other chemokines and receptors, along with reduced intensity of myocarditis, as compared to those with other
CXCL9/CXCL10 genotypes.
Conclusions: Results may indicate that genotypes associated to reduced risk in closely linked CXCL9 and CXCL10 genes may
modulate local expression of the chemokines themselves, and simultaneously affect myocardial expression of other key
chemokines as well as intensity of myocarditis. Taken together our results may suggest that CXCL9 and CXCL10 are master
regulators of myocardial inflammatory cell migration, perhaps affecting clinical progression to the life-threatening form of
CCC.
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Introduction
Approximately 8 million people are infected with the protozoan
parasite Trypanosoma cruzi [1] in Central and South America, with
an estimated 300,000 cases in the USA alone. T. cruzi is a major
cause of heart disease and cardiovascular-related deaths in
endemic areas located in Latin America, with approximately
50,000 fatalities per year due to Chronic Chagas cardiomyopathy
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(CCC) [2]. The high parasite load typical of the acute infection
results in a strong innate and adaptive immune response against T.
cruzi, leading to the control - but not the complete elimination - of
tissue and blood parasitism, establishing a low-grade chronic
persistent infection [3]. CCC is an inflammatory cardiomyopathy
that affects approximately 30% of infected individuals and occurs
5–30 years after acute infection, while the remaining patients
develop digestive disorders (5–10%) or remain asymptomatic
(ASY, 60–70%) [4]. It has been observed that the occurrence of
myocarditis is correlated with clinical severity, ASY patients
having minimal inflammation, while patients with advanced CCC
display frequent and intense myocarditis [5]. Approximately 1/3
of patients developing CCC present a particularly lethal form of
dilated cardiomyopathy, with shorter survival than idiopathic
dilated cardiomyopathy [6]. In addition, CCC is associated with a
worse prognosis and survival than other cardiomyopathies of non-
inflammatory etiology (NIC) [7]. Although currently used
trypanocidal drugs are effective in the treatment of acute or
recent infection in children their efficacy in halting the progression
of cardiac lesions has not been established yet [8]. Data suggest
that the mononuclear inflammatory infiltrate, associated with
cardiomyocyte destruction and fibrosis observed only in CCC
myocardium, plays a major role in the development and
progression of the disease [5,9].
Histologically, CCC myocardium displays a diffuse myocarditis
with focal aspects; a mononuclear infiltrate, intense heart fiber
damage, prominent fibrosis and scarcity of T. cruzi parasites
(reviewed in [10]). The inflammatory infiltrate of CCC heart
lesions is composed mainly by T cells and macrophages [9,11].
Heart-infiltrating T cells and other mononuclear cells predomi-
nantly produce TNF-a and IFN-c [12,13,14], and a similar
increase in IFN-c and TNF-a is seen in cardiac tissue from
animals infected with T. cruzi [15,16]. An increased number of
IFN-c-producing cells is found in peripheral blood mononuclear
cells (PBMC) of CCC patients [14,17]. Together, data suggest a
predominance of Th1-type T cells in CCC myocardium and
peripheral blood [18]. However, the factors that determine the
migration and accumulation of the Th1-type T cell in CCC heart
tissue are still obscure. The possibility that chronic myocardial
inflammation and tissue damage in CCC are a consequence of
recognition of T. cruzi antigen on heart tissue must be entertained.
However, T. cruzi DNA, a surrogate marker of the presence of
living parasites, has been equally detected in hearts of CCC and
ASY patients [19,20], indicating that mere parasite presence in the
heart is not sufficient for inducing inflammatory tissue damage.
Both T. cruzi-specific [21] or heart antigen (cardiac-myosin) -
specific T cells - crossreactive with T. cruzi antigen [22] - have been
identified in the myocardial inflammatory infiltrate. Since both
cardiac proteins and T. cruzi antigen are present in hearts of both
CCC and ASY patients, some other factor distinct from antigen
availability must control the difference in inflammation and
disease progression between Chagas disease patients.
Given the important role of chemokines such as CCL3, CCL4,
CCL5 and CXCL9 and CXCL10 in tissue accumulation of
CCR5+ and/or CXCR3+ Th1-type T cells [23], it is possible that
the development and maintenance of the tissue-damaging Th1-
rich mononuclear infiltrate in CCC myocardium could be a
consequence of the in situ expression of chemokine ligands to those
receptors. Indeed, increased mRNA levels of CC and CXC
chemokines have been detected in the heart tissue of T. cruzi-
infected mice (reviewed in [24,25]). Additionally, increased
numbers of CCR5+ CXCR3+ CD4+ and CD8+ T cells producing
IFN-c and/or TNF-a were found in PBMC from CCC patients,
as compared with ASY patients [26]. Previous studies from our
group showed that gene expression levels of IFN-c-inducible
chemokines CXCL9 and CXCL10 were significantly up-regulated
in CCC myocardium [27]. Local production of CXCL9 and
CXCL10 by mononuclear infiltrating and stromal cells leads to
the recruitment of effector Th1 lymphocytes into inflamed tissues
in delayed hypersensitivity reactions (reviewed in [28]). Converse-
ly, functional polymorphisms controlling expression, and loss-of-
function deletions in protein-coding regions of genes encoding
chemokines and their receptors have been associated with
development of several inflammatory and autoimmune diseases
[29,30,31]. This indicates that chemokine polymorphisms can
control organ-specific inflammatory damage -even in the presence
of similar amounts of antigen- by means of regulating inflamma-
tory cell influx. We therefore hypothesized that an imbalance at
the Th1-associated chemokine-chemokine receptor axis - perhaps
of genetic origin - could play a role in the maintenance of the
inflammatory infiltrate in CCC patients.
Here, we analyzed cell surface staining and gene expression of
the chemokine receptors CXCR3 and CCR5, associated to the
Th1 phenotype, and their ligands. Conversely, we also studied the
CCR4 and CCR8 receptors, associated to the Th2 phenotype,
and their chemokine ligands, as well as the chemokine receptor
CCR7, associated to memory phenotypes, and its ligands in
myocardial samples form end-stage CCC and non-inflammatory
cardiomyopathy patients, as well as control subjects. In addition,
we analyzed single-nucleotide polymorphisms (SNPs) for genes
encoding 8 such chemokines and receptors in a cohort of Chagas
disease patients stratified according to clinical form (ASY, CCC)
and presence of ventricular dysfunction among CCC patients.
Methods
Ethics Statement
The protocol was approved by the Institutional Review Board
of the University of Sa˜o Paulo School of Medicine (Protocol
number 739/2005 and 0324/2009) and written informed consent
Author Summary
Chronic Chagas cardiomyopathy (CCC) is an inflammatory
heart disease that affects millions in Latin America, and in
growing numbers in USA and Europe. Survival among CCC
patients is shorter than among patients with cardiomyop-
athy of non-inflammatory etiology. This suggests that the
inflammatory cell influx plays an important pathogenic
role in CCC. However, little is known about the factors that
maintain this myocardial inflammation. We hypothesized
that Th1 T cell-attracting chemokines, involved in driving
leukocyte migration, could play a role in myocardial
inflammation. Herein, we have analyzed expression of
several chemokines and receptors in heart tissue from
patients with CCC and controls. We found inflammatory
cells expressing chemokines and receptors consistent with
Th1 T cell influx into CCC myocardium. mRNA expression
levels of the chemokine CXCL9 correlated with inflamma-
tion. We also studied whether genetic variations in these
genes could be associated to CCC development. Polymor-
phisms in CXCL9, CXCL10 and CCR5 were associated to
differential risk of progression to the more severe form of
CCC. Polymorphisms of CXCL9 and CXCL10 were also
associated to the intensity of myocardial inflammation and
chemokine expression. These results suggest that such
chemokines may be master regulators of myocardial
inflammatory cell migration, perhaps affecting clinical
progression to severe CCC.
Chemokines in Chagas Cardiomyopathy Myocardium
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was obtained from the patients. In the case of samples from heart
donors, written informed consent was obtained from their families.
Patients and sample collection
All Chagas disease patients were considered serologically
positive for antibodies against T. cruzi on the basis of results of
at least 2 of 3 independent tests (EIA [Hemobio Chagas;
Embrabio Sa˜o Paulo], indirect immunofluorescence assay [IFA-
immunocruzi; Biolab Merieux], and indirect hemagglutination test
[Biolab Merieux]). All Chagas disease patients underwent
standard electrocardiography and echocardiography. Echocardi-
ography was performed in the hospital setting using an Acuson
Sequoia model 512 echocardiographer with a broad-band
transducer. The left ventricular dimensions and regional and
global function evaluations were performed using a 2-dimension
and M-mode approach, in accordance with the recommendations
of the American Society of Echocardiography. Patients with CCC
presented with abnormal electrocardiography findings that ranged
from typical conduction abnormalities (right bundle branch block
and/or left anterior division hemiblock) to severe arrhythmia [32].
A group of patients also presented varying degrees of ventricular
dysfunction classified on the basis of left ventricular ejection
fraction, with all other causes of ventricular dysfunction/heart
failure excluded. All asymptomatic (ASY) subjects had normal
echocardiograph and echocardiogram findings, chest radiographs
with no evidence of cardiac enlargement, and normal findings of
radiographs of the esophagus and colon.
Myocardial left ventricular free wall heart samples were
obtained from end-stage heart failure CCC patients (n = 14,
positive for antibodies against T. cruzi and born in endemic areas
for Chagas disease, five males and nine females, mean age
47.2614.6 years, Table 1) and end-stage heart failure patients
with non-inflammatory cardiomyopathies (NIC, n = 8, five
patients with idiopathic dilated cardiomyopathy and three patients
with Ischemic cardiomyopathy, all seronegative for T. cruzi, eight
males, mean age 53.367.5 years, Table 1). Control adult heart
tissue from the left ventricular-free wall was obtained from
nonfailing donor hearts (N, n = 6, males, mean age 32.2612.8
years, Table 1) not used for cardiac transplantation due to size
mismatch with available recipients. Hearts were explanted at the
time of heart transplantation at the Heart Institute - InCor,
University of Sa˜o Paulo School of Medicine, Sa˜o Paulo, SP, Brazil.
For histological studies, fresh tissues were fixed in buffered
formalin solution and paraffin-embedded; for immunofluores-
cence, fresh samples were maintained in a 30% sucrose solution
for approximately 30 min at 4uC; then they were transferred to
OCT Tissue Tek freezing medium and immediately frozen in
isopentane and stored at 280uC. For mRNA extraction, samples
were quickly dissected, and myocardial tissue was frozen in liquid
nitrogen and stored at 280uC. For SNP genotyping, genomic
DNA was obtained from myocardial left ventricular free wall heart
samples using the QIAamp DNA Blood Max Kit (Qiagen, Hilden,
Germany) and stored at 220uC.
Blood samples were collected from the patients who were
categorized as being ASY (n = 151, 72 males, mean age 50.863.6
years, and 79 females, mean age 54.163.5 years) or as having
CCC (n = 174, 83 males, mean age 50.860.5 years, and 91
females, mean age 48.066.6 years) on the basis of clinical,
radiological, electrocardiographic (ECG), echocardiographic cri-
teria and all of patients were serologically positive for antibodies
against T. cruzi and born in endemic areas for Chagas disease. All
of ASY patients had normal ECG findings and a normal left
ventricular ejection fraction (LVEF) at the time of echocardiog-
raphy, as well as normal findings for chest, esophagus and colon
radiography. The CCC patients presented with typical ECG
findings (right bundle branch block and/or left anterior division
hemiblock and were classified as having moderate (LVEF.40%,
n = 79) or severe (LVEF#40%), n = 95) CCC. Genomic DNA was
extracted by the dodecyltrimethyl ammonium bromide/hexade-
cyltrimethylammonium bromide method and stored at 220uC.
Histological and Immunofluorescence staining/Confocal
analysis
Individual 5-mm sections of paraffin-embedded tissue or
cryosections of frozen myocardial fragments were applied to
microscope slides. Slides were subjected either to hematoxylin-
eosin or immunofluorescence staining. Standard hematoxylin-
eosin staining was performed for evaluation of the intensity and
location of the inflammatory infiltrate. Slides were evaluated and
scored for the intensity of myocarditis, fibrosis and hypertrophy.
Slides for immunofluorescence were washed in phosphate-buffered
saline (PBS) and blocked with PBS-2% bovine serum albumin.
Slides were incubated overnight at 4uC with the primary
monoclonal antibodies anti-CD3, anti-CD4, anti-CD8, anti-
CCR5, anti-CXCR3, anti-CCR4, anti-CCL5 or anti-CXCL9
(R&D Systems, Minneapolis, MN, USA); after washing, slides
were incubated with the secondary antibody, anti-mouse IgG
conjugated to AlexaFluor 633 (Invitrogen, Carlsbad, CA, EUA)
and 49,69-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Stein-
hein, Germany) for nuclear staining. Slides were mounted using
antifade mounting medium (Hydromount, National Diagnostics,
Atlanta, GA, USA). Fluorescent images were acquired using UV/
Laser excitation on an LSM/Meta 510 Zeiss microscope, with an
oil immersion objetive (636, 1.25 numerical aperture). For each
section, the area with most uniform infiltrate was selected for
analysis. Within this inflammatory area, minimums of five fields
were acquired. Image analysis and processing were performed
using LSM Image Examiner software (Carl Zeiss, Standort
Go¨ttingen, Germany). Omission of primary antibody and
replacement with non-immune mouse IgG was used to confirm
the lack of nonspecific staining.
RNA isolation, reverse transcription and quantitative real-
time polymerase chain reaction (real-time qPCR)
Total RNA was extracted from 56565 mm myocardial
samples using the TrizolH method (Life Technologies Inc., Grand
Island, NY). The RNA was quantified using NanoDrop Spectro-
photometry (Thermo Scientific), and treated with Rnase-free
DNase I (USB, Ohio, USA). cDNA was obtained from 5 mg total
RNA using Super-script IITM Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). We designed forward and reverse primers
for real-time qPCR assays using the Primer Express software
(Applied Biosystems, Foster City, CA, USA; Table S1). Real-time
qPCR reactions were carried out in an ABI Prism 7500 Sequence
Detection system (Applied Biosystems) using the SYBR Green
PCR Master Mix (Applied Biosystems), as described [33]. For all
genes, we constructed standard curves and determined the slope to
calculate the PCR efficiency. All the samples were tested in
triplicate with the GAPDH, previously shown to display little
variance among human myocardial tissue samples [27], as the
reference gene for normalization of data, and relative expression of
each mRNA was calculated with the 22DDCt method [34], using
expression in six normal donor hearts as calibrator.
SNP genotyping
We searched for polymorphisms in our target genes preferen-
tially in putatively regulatory regions such as 59 and 39untranslated
Chemokines in Chagas Cardiomyopathy Myocardium
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regions (UTR) or intronic regions, and which had previously been
studied in disease association studies. This was the case of CXCL9
rs10336, CXCL10 rs3921, CCL5 rs2107538 and CCR5 rs1799988
[35,36,37]. In the cases of target genes where no previous study
was found - CCL4, CCL17, CCL19 and CXCR3 - the selected SNP’s
(CCL4 rs1719153, CCL17 rs223827, CCL19 rs3136658 and
CXCR3 rs2280964) were located in putatively regulatory sites,
with minimum allele frequencies above 0.2 in the CEU
(Caucasian) and Yoruba (YRI) populations at the HapMap
database (site http://hapmap.ncbi.nlm.nih.gov) (Table S2). Ge-
notyping was performed using the designed assay of the TaqMan
allelic discrimination technique (ABI 7500, Applied Biosystem,
Foster City, USA) and evaluated according to the manufacturer’s
instructions. The following SNPs were tested: SNP CCL4
rs1719153 (part nu. C_12120537_10), CCL5 rs2107538 (part nu.
C__15874407_10), CCR5 rs1799988 (part nu. C__11988170_10),
CXCL9 rs10336 (part nu. C_486222_10), CXCL10 rs3921 (part nu.
C_497062_10), CXCR3 rs2280964 (part nu. C_15874773_10),
CCL17 rs223827 (part nu. C_2845028_10) and CCL19 rs3136658
(part nu. C__25981926_10) CCL4, CXCL9 and CXCL10 are
mapped to the 39 untranslated region (UTR); CCL5 and CCR5
are mapped to the 59 UTR; CCL17, CCL19 and CXCR3 are
mapped to intronic regions.
Statistical analysis
Values of the relative expression of each mRNA in the CCC
and NIC groups were compared with the Mann-Whitney U test.
Correlation analysis was performed by Spearman’s nonparametric
Table 1. Characteristics of patients and control donors whose myocardial samples were used in gene expression studies.
Internal n6 Age Sex
Disease
group EF Fibrosis LVDD Hypertrophy Myocarditis ANPRelative BNP expression
CCC patients
CCC1 15 M CCC 17 1+ 62 Y 1+ 5.0 221.5
CCC2 44 F CCC 21 1+ 70 Y 1+ 223.6 780.6
CCC3 61 F CCC 15 1+ 76 Y 1+ 2.2 51.2
CCC4 23 F CCC 39 2+ 78 Y 2+ 55.8 402.6
CCC5 50 M CCC 11 2+ 82 Y 2+ 61.0 468.8
CCC6 49 F CCC 37 3+ 77 Y 3+ 57.1 268.6
CCC7 49 F CCC 15 2+ 83 Y 3+ 15.0 90.8
CCC8 28 M CCC 21 2+ 68 Y 2+ 2.6 8.1
CCC9 54 F CCC 36 2+ 62 Y 2+ 155.3 828.2
CCC10 58 M CCC 29 2+ 64 Y 2+ 88.2 832.6
CCC11 57 M CCC 29 1+ 71 Y 2+ 11.8 65.0
CCC12 60 F CCC 20 2+ 72 Y 3+ 7.4 264.6
CCC13 61 F CCC 27 1+ 77 Y 0 157.1 1729.1
CCC14 50 F CCC 23 2+ 61 Y 3+ 198.5 1844.1
NIC patients
NIC1 53 M IDC 19 1+ 77 Y 0 53.0 160.1
NIC2 38 M IDC 16 1+ 88 Y 0 510.0 425.2
NIC3 63 M IDC 38 1+ ND Y 0 1.2 13.6
NIC4 55 M IDC 25 3+ 51 Y 0 4.4 29.8
NIC5 58 M IDC 16 2+ 99 Y 0 38.3 179.7
NIC6 62 M IC 37 2+ 75 Y 0 4.0 28.1
NIC7 61 M IC 33 3+ 79 Y 0 0.1 0.2
NIC8 52 M IC 20 3+ 62 Y 0 8.8 546.2
Control individuals
N1 46 M Normal ND 0 ND N 0 - -
N2 40 M Normal ND 0 ND N 0 - -
N3 22 M Normal ND 0 ND N 0 - -
N4 20 M Normal ND 0 ND N 0 - -
N5 45 M Normal ND 0 ND N 0 - -
N6 20 M Normal ND 0 ND N 0 - -
Age (years). M (male). F (female). CCC (Chronic Chagasic Cardiomyopathy). NIC (Non-inflammatory Cardiomyopathy). IDC (Idipathic Dilated Cardiomyopathy). IC
(Ischemic Cardiomyopathy). Normal heart donors were subject to ventilator and vasoactive drugs, and had been under life support for an average of 48 hours.
Characterization of the samples as myocarditis, fibrosis and hypertrophy; reference values for the presence of myocarditis and fibrosis: 0: absent; 1+: slight; 2+:
moderate; 3+: intense; hypertrophy: Y: yes N: no. EF (Ejection Fraction) was always less than 40%. LVDD (left ventricle diastolic diameter) normal reference value:
diameter 39–55 mm. Values of mRNA expression (RT-qPCR) of the atrial natriuretic peptide (ANP) and the brain natriuretic peptide (BNP). -, Control samples were used
as calibrators in the RT-qPCR reaction and have no relative expression value using the 22DDCt calculation method as described in Methods.
doi:10.1371/journal.pntd.0001867.t001
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correlation test with SPSS version 14.0 software (SPSS, Chicago,
III). Associations between patient groups and genotypes or a
specific allele were analyzed by the x2 statistical test, along with the
relevant odds ratio (OR) and 95% confidence interval (CI).
Fisher’s exact test was used when at least one value in the
contingency table was,5. We considered differences as significant
when the p value was less than 0.05 and the CI did not cross 1.
Hardy-Weinberg equilibrium (HWE) was determined by compar-
ing the observed number of different genotypes with the expected
number under the HWE for the estimated allele frequency.
Results
Patient and sample features
While myocardial sections from both CCC and NIC groups
displayed cardiomyocyte hypertrophy and fibrosis upon histopath-
ological analysis, lymphocytic myocarditis was only observed
among samples from CCC patients (Figure 1A, Table 1). Although
all CCC patients presented clinically similar end-stage heart
disease, variable degrees of lymphocytic myocarditis were
observed. No significant differences were found in age, ejection
fraction (EF) or left ventricular diastolic diameter (LVDD) between
the two groups, and mRNA expression of the natriuretic peptides
ANP and BNP was substantially upregulated in comparison to
control myocardium samples (Table 1), indicative of activation of
the embryonic/hypertrophic gene expression pattern consistent
with advanced heart failure.
Heart-infiltrating mononuclear express multiple
chemokines and chemokine receptors
Using immunofuorescence confocal microscopy, we assessed the
surface phenotype of mononuclear cells in the myocardial
inflammatory infiltrate of CCC samples (Figure 1B and Figure
S1). CD3+, CD4+ and CD8+ T cells were abundant in CCC
myocardium, very scarce in NIC samples and essentially absent in
control samples (N), in line with histopathological data (Figure S1).
We observed mononuclear cells staining for CXCR3 and CCR5-
typical of Th1 T cells - as well as CCR4 – more commonly
described as a marker of Th2 T cells in CCC myocardium
(Figure 1B). CXCR3 staining was also observed in non-mononu-
clear, stromal cells in CCC heart tissue (Figure 1B, Figure S1). In
addition, we observed in situ expression of the chemokines CCL5
and CXCL9, ligands of the CCR5 and CXCR3 receptors, in
mononuclear cells infiltrating the myocardium of CCC patients
(Figure 1B). We could also observe CCL5 staining in endothelial
cells lining what seems to be a blood vessel in CCC myocardium
(Figure 1B, Figure S1). Specificity of the tested antibody staining is
shown at Figure 1B.
Multiple T cell chemoattractant chemokines and their
receptors are expressed in heart tissue from CCC patients
We assessed mRNA expression of CCR5 and CXCR3
chemokine receptors associated with inflammatory, Th1-type T
cells, as well as the chemokine receptors CCR4 and CCR8, which
are associated to a Th2 phenotype, and CCR7, a chemokine
receptor associated to memory phenotypes, in myocardium tissue
from CCC, NIC and control samples using real-time qPCR.
Figure 2A shows that mRNA expression levels of CCR5, CXCR3
and CCR4 were significantly higher in CCC myocardial tissue
that of NIC patients and normal donors, which corroborated with
the immunofluorescence detection data (Figure 1B). The expres-
sion of CCR8 mRNA did not differ significantly between the CCC
and NIC groups (Figure 2A). The expression of CCL1 (CCR8
ligand) was undetectable in CCC, NIC and control samples.
The expression of mRNA encoding CCR5 ligands (CCL3,
CCL4 and CCL5), CXCR3 ligands (CXCL9 and CXCL10), the
CCR4 ligand CCL17 and the CCR7 ligand CCL19 was
significantly higher in CCC than in NIC myocardium
(Figure 2B). Of note, median CCL5 expression in CCC
myocardium was over 100-fold higher than normal controls.
The expression of CXCL9, CXCL10, CCL17 and CCL19 in
CCC samples was between 10 and 100-fold higher than normal
control samples. Of interest, mRNA levels of CCL21, another
CCR7 ligand, were 5-fold higher in samples from both CCC and
NIC heart tissue than in samples from control individuals
(Figure 2B). As the expression of CCR7 was undetectable in
myocardium samples from control individuals, the relative
expression of this receptor could not be subjected to relative
quantification using the DDCt method. We found that the average
DCt value of CCR7 in heart tissue from the CCC patients was
significantly lower than in NIC myocardium (14.5262.9 versus
18.3462.5; p = 0.01, data not shown), indicating that this gene
also displayed increased expression in CCC as compared to NIC
myocardium.
We also analyzed whether chemokine expression was associated
with histopathological parameters in CCC heart tissue. We found
a positive correlation between mRNA expression of CXCL9 and
the histopathologically assessed intensity of myocarditis (Figure 3).
CXCL9 also showed a positive correlation with chemokine
receptors CXCR3, CCR4 and CCR5, as well as chemokines
CCL5, CXCL10 and CCL17. In addition, positive correlations
were also found between CXCR3 and CCR5; the chemokine
receptors and several of their ligands; and between several CC and
CXC chemokines (Figure S2).
Given the focal nature of the myocarditis and fibrosis in CCC
myocardium, we assessed the gene expression profile in different
sites of the left ventricular free wall of three patients. This profile
was found to be essentially concordant in samples from different
sites of the myocardium of the same patients (Table S3). We also
found a positive correlation of global gene expression between
almost all CCC samples (Figure S3), indicating that most CCC
patients share a similar pattern of gene expression, with individual-
specific variation in global magnitudes of expression. These global
magnitudes of gene expression seem thus to be maintained in
distinct regions of the myocardium (Table S3).
Genotypes of SNPs of CCR5, CXCL9 and CXCL10 are
associated with CCC severity
In order to investigate whether the observed variation in global
magnitudes of gene expression was due to genetic polymorphisms,
we evaluated single nucleotide polymorphisms in the most highly
expressed genes in CCC heart tissue (fold expression .10 as
compared to normal donor samples). We compared genotypic and
allele frequencies in the CCC and ASY groups of a sample of 325
Brazilian chronic Chagas disease patients, and also stratified CCC
patients according to their LVEF status, comparing the two CCC
groups according to severity of ventricular dysfunction: those
patients classified as severe (LVEF#40%) or moderate
(LVEF.40%) CCC. All the SNPs were in HWE in both CCC
and ASY subjects.
There are no significant differences in genotype and allele
frequencies of SNP CXCL9 rs10336 between CCC and ASY
(Table 2). However, the CXCL9 rs10336 CC genotype was
significantly less frequent among the severe CCC than in the
moderate CCC group (OR, 0.47 [95% CI, 0.25–0.87] Table 2).
Accordingly, the CXCL9 rs10336 C allele was significantly less
frequent among the severe CCC than in the moderate CCC
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group. Thus, both the C allele and the CC genotype are associated
to a lower risk for severe CCC.
There are no significant differences in GG and CG frequencies of
SNP CXCL10 rs3921 polymorphism in the patients with CCC when
compared with ASY patients (Table 3). However, the CXCL10
rs3921 GG genotype was significantly less frequent among the severe
CCC than in the moderate CCC group (OR, 0.41 [95% CI, 0.22–
0.79] Table 3). Accordingly, the CXCL10 rs3921 G allele was
significantly less frequent among the severe CCC than in the
moderate CCC group. Therefore, both the G allele and the GG
genotype apparently are associated to a lower risk for severe CCC.
Conversely, the CXCL10 rs3921 C allele was significantly more
frequent between the severe CCC than in the moderate CCC group,
thus the CC genotype is associated to a higher risk for severe CCC.
The genotype and allele frequencies of the CCR5 rs1799988 CT
polymorphism are given in Table 4. The genotype and allele
distribution of this polymorphism in the CCC patients was not
significantly different from that found among ASY patients. The
CCR5 rs1799988 CC genotype was significantly more frequent
among the severe CCC than in the moderate CCC group (OR,
2.31 [95% CI, 1.14–4.67] Table 4). Accordingly, the CCR5
rs1799988 C allele was significantly more frequent among the
severe CCC than in the moderate CCC group. Results indicate
that both the C allele and the CC genotype of CCR5 rs1799988 are
associated to a higher risk for severe CCC.
No differences in genotypic and allelic frequencies were found
in the studied SNPs in CCL4, CCL5, CXCR3, CCL17 and CCL19
between CCC and ASY patients (Tables S4, S5, S6, S7 and S8).
Figure 1. Histopathological analysis and localization of CCR5+, CXCR3+, CCR4+, CCL5+ and CXCL9+ cells in heart tissue. Severe
myocarditis with intense mononuclear inflammatory infiltrate in the heart tissues of CCC patient, and absence of myocarditis in the heart tissues of
NIC patients and individuals without cardiomyopathies (N). In (A), imagens representative of heart fragments from CCC, NIC and N individuals.
Haematoxylin-eosin stain. Representative images of immunofluorescence confocal microscopy from heart tissue sections from CCC and NIC (B).
Sections were stained with primary antibodies against CCR5, CXCR3, CCR4, CCL5 and CXCL9 stained with AF633-conjugated anti-mouse IgG (red) and
counterstained with DAPI (blue), as described in Methods. CTR- IgG isotype controls.
doi:10.1371/journal.pntd.0001867.g001
Figure 2. Expression of chemokines and chemokine receptors in myocardium. Expression of chemokine receptors (A) in CCC and NIC
myocardium. Expression of chemokines (B) in CCC and NIC myocardium. Real-time qPCR analysis of mRNA levels expression in CCC and NIC
myocardium. After normalization to GAPDH mRNA, the relative expression was plotted in comparison to N group and data were calculated with the
22DDCt method, as described in Methods. The horizontal bar stands for the median. Dotted lines indicate two-fold increase or decrease expression as
compared with the control group.
doi:10.1371/journal.pntd.0001867.g002
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Protective CXCL9 and CXCL10 polymorphisms are
associated with lower myocardial chemokine expression
and myocarditis
We next analyzed whether CXCL9 and CXCL10 polymorphisms
associated to decreased or increased risk of CCC development
conveyed different levels of chemokine/chemokine receptor
expression in CCC heart samples. The study could not be done
for CCR5 because there was only one TT patient. We found that
myocardial expression of CXCL9 mRNA among samples from
patients bearing the protective SNP CXCL9 rs10336 genotype CC
(n = 5) was 5-fold lower than that of patients bearing the TT or CT
genotypes. We also found that CCL3, CCL5, CXCL10, CXCR3,
CCL17 and CCR4 were 2–6-fold less expressed in SNP CXCL9
rs10336 genotype CC as compared with samples from patients
bearing the TT or CT genotypes (Figure 4A).
Likewise, we found that myocardial CXCL10 expression among
samples from patients bearing the protective SNP CXCL10 rs3921
genotype GG (n = 4) was 3-fold less intense than that of patients
bearing the CC or CG genotypes. We also found that CCL3,
CXCL9 and CCR4 were 2–3 fold less expressed in samples from
patients carrying SNP CXCL10 rs3921 genotype GG as compared
with those from patients bearing the CC or CG (Figure 4B).
Discussion
Although the pathogenic role of myocarditis in CCC is well
established, the factors that lead to the maintenance of the
myocardial infiltrate have remained unclear. In this paper, we
report that mononuclear cells expressing CD3, CD4, CD8,
CCR5, CXCR3, CCR4, CXCL9 and CCL5 are found in CCC
myocardial tissue. We also found increased mRNA expression of
CXCL9, CCL5, the above mentioned chemokine receptors and
several of their other chemokine ligands. CXCL9 expression
correlated with the intensity of the myocardial infiltrate, as well as
with the mRNA expression of CXCR3, CCR5, CCR4, CCR7
and several of their ligands. The closely linked CXCL9 rs10336 CC
and CXCL10 rs3921 GG genotypes were associated with protection
from severe CCC, while CCR5 rs1799988 CC is associated with
increased risk for development of severe CCC. Myocardium
samples carrying the protective CXCL9 rs10336 CC genotype
expressed significantly less mRNA encoding CXCL9 itself, along
with CCL3, CCL5, CXCL10, CXCR3, CCL17 and CCR4, than
samples carrying other CXCL9 rs10336 genotypes. Similarly,
samples carrying the protective CXCL10 rs3921 GG genotype
expressed less mRNA encoding CCL3, CXCL9, CXCL10 and
CCR4 than samples carrying other CXCL10 rs3921 genotypes.
These results suggest that CXCL9 (and possibly CXCL10) may
Figure 3. Correlation between histopathologically assessed
intensity of myocarditis and mRNA expression of CXCL9 in CCC
myocardium. Two-tailed p value obtained with Spearman’s nonpara-
metric correlation. n = 14.
doi:10.1371/journal.pntd.0001867.g003
Table 2. Genotype and allele frequencies for the CXCL9 rs10336 polymorphism in patients with Chagas disease.
CCC
ASY Moderate Severe All
CXCL9 (rs10336) (n = 146) (n = 79) (n = 95) (n = 174) x2 p OR(95%CI)
Genotype
TT 13(9) 4(5) 10(10) 14(8)
TC 71(49) 36(46) 55(58) 91(52)
CC 62(42) 39(49) 30(32) 69(40)
Genotype comparison
TT plus TC vs. CC
ASY vs. CCC 0.25 0.61 0.89 (0.56–1.39)
LVEF.40% vs. LVEF#40% 5.70 0.01* 0.47(0.25–0.87)
Allele
T 97(33) 44(28) 75(39) 119(34)
C 195(67) 114(72) 115(61) 229(66)
Allele comparison T vs. C
ASY vs. CCC 0.06 0.79 0.95(0.68–1.33)
LVEF.40% vs. LVEF#40% 5.81 0.002* 0.59(0.37–0.93)
CCC patients were further stratified by left ventricular ejection fraction values.
Data are no. (%) of patients. Moderate CCC has LVEF.40%. Severe CCC has LVEF#40%. CI, confidence interval. OR, odds ratio.
doi:10.1371/journal.pntd.0001867.t002
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Table 4. Genotype and allele frequencies for the CCR5 rs1799988 polymorphism in patients with Chagas disease.
CCC
ASY Moderate Severe All
CCR5 (rs1799988) (n = 150) (n = 78) (n = 93) (n = 171) x2 p OR(95%CI)
Genotype
CC 45(30) 15(19) 33(35) 48(28)
CT 63(42) 43(55) 46(49) 89(52)
TT 42(28) 20(26) 14(15) 34(20)
Genotype comparison
CC plus CT vs. TT
ASY vs. CCC 2.91 0.08 0.63(0.38–1.07)
LVEF.40% vs. LVEF#40% 2.98 0.08 0.51(0.23–1.10)
TT plus CT vs. CC
ASY vs. CCC 0.14 0.70 0.91 (0.56–1.47)
LVEF.40% vs. LVEF#40% 5.55 0.01* 2.31(1.14–4.67)
Allele
C 153(51) 73(47) 112(60) 185(54)
T 147(49) 83(53) 74(40) 157(46)
Allele comparison C vs. T
ASY vs. CCC 0.61 0.61 0.88(0.64–1.20)
LVEF.40% vs. LVEF#40% 6.15 0.01* 0.58(0.37–0.89)
CCC patients were further stratified by left ventricular ejection fraction values.
Data are no. (%) of patients. Moderate CCC has LVEF.40%. Severe CCC has LVEF#40%. CI, confidence interval. OR, odds ratio.
doi:10.1371/journal.pntd.0001867.t004
Table 3. Genotype and allele frequencies for the CXCL10 rs3921 polymorphism in patients with Chagas disease.
CCC
ASY Moderate Severe All
CXCL10 (rs3921) (n = 149) (n = 77) (n = 93) (n = 170) x2 p OR(95% CI)
Genotype
CC 15(10) 4(5) 14(15) 18(11)
CG 75(50) 35(45) 52(56) 87(51)
GG 59(40) 38(50) 27(29) 65(38)
Genotype comparison
CC plus CG vs. GG
ASY vs. CCC 0.06 0.80 0.94 (0.60–1.48)
LVEF.40% vs. LVEF#40% 7.36 0.006* 0.41(0.22–0.79)
GG plus CG vs. CC
ASY vs. CCC 0.02 0.87 1.05 (0.51–2.18)
LVEF.40% vs. LVEF#40% # 0.04* 3.23(1.01–10.28)
Allele
C 105(35) 43(28) 80(43) 123(36)
G 193(65) 111(72) 106(57) 217(64)
Allele comparison C vs. G
ASY vs. CCC 0.06 0.80 0.95(0.69–1.32)
LVEF.40% vs. LVEF#40% 8.30 0.003* 0.51(0.32–0.81)
CCC patients were further stratified by left ventricular ejection fraction values.
Data are no. (%) of patients. Moderate CCC has LVEF.40%. Severe CCC has LVEF#40%. CI, confidence interval. OR, odds ratio.
doi:10.1371/journal.pntd.0001867.t003
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play an important role modulating the CXCR3/CCR5 chemo-
kine axis and the intensity of mononuclear cell migration to CCC
myocardium.
The identification of CCR5+ and CXCR3+ mononuclear cells,
corroborated by the increased mRNA expression of the same
chemokine receptors (Figure 1 and 2) in CCC myocardium, is in
line with the prominent finding of mononuclear cells secreting
IFN-c and TNF-a in CCC heart tissue [13,14,38], and together
are consistent with the influx of Th1 cells expressing these
receptors. CCR5 is known to be expressed by macrophages, T and
B cells, while CXCR3 is expressed by T and B cells; such cells may
thus have been attracted by the respective chemokine ligands [39].
Indeed, CCC patients display increased numbers of CD4+ and
CD8+ T cells coexpressing CXCR3/CCR5 and IFN-c/TNF-a in
peripheral blood when compared to T. cruzi-seropositive ASY/
IND individuals [26]. In addition, CXCR3 expression was also
observed in stromal cells from CCC myocardium (Figure 1B), in
line with reports of CXCR3 expression in non-lymphoid cells [40],
which may have contributed to the increased CXCR3 mRNA
expression in CCC heart tissue. The high expression of CCR4 and
CCL17 (Figure 2) is consistent with the presence of Th2 T cells
[41]. However, it is unlikely that such cells are functional Th2 T
cells, since preliminary observations indicate that IL-4, IL-5, and
IL-13 are not expressed in CCC heart tissue (unpublished results).
It is possible that other cell types, such as endothelial cells or
regulatory T cells, may be responsible for CCR4 and CCL17
expression in CCC myocardium [42,43]. The finding that CCR7
and its ligands CCL19 and CCL21 were upregulated in CCC
myocardium is consistent with a role in the recruitment of CCR7+
cells from the periphery (Figure 2B). CCR7 can be expressed by
naı¨ve or central memory T cells, along with endothelial cells,
fibroblasts and B cells [44]. Endothelial expression of CCR7
ligands is a known chemoattractant for CCR7+ central memory
and even naı¨ve T cells for migration into inflamed tissue [44].
CCL21, whose mRNA expression is upregulated in myocardium
samples of both CCC and NIC patients, is also a chemoattractant
for CCR7+ fibrocytes [45], inducing expression of type I collagen
in vitro [46] and thus promotes fibrosis. CCL21 expression may
thus be one of the stimuli driving myocardial fibrosis and
pathological remodeling both in CCC and NIC.
The identification of CCL5+ and CXCL9+ mononuclear cells
(Figure 1B), as well as the mRNA expression of these and other
CCR5 and CXCR3-binding chemokines (Figure 2B) is in line with
the observed accumulation of CCR5+ and CXCR3+ mononuclear
cells in CCC myocardium. CXCR3 and CCR5-binding chemo-
kines have been postulated to play a role in recruiting polarized
Th1 T cells to sites of chronic inflammation [41], and most of
them are also IFN-c-inducible chemokines [47]. Interestingly,
discrete staining for CCL5 was also observed in structures
consistent with microvascular endothelium (Figure 1B), suggesting
a role for this chemokine, and possibly other CCR5 ligands, in the
migration and accumulation of Th1 cells in CCC heart tissue.
CCL3, CCL4, CCL5, CXCL9 and CXCL10 are produced by
stimulated T lymphocytes, monocytes/macrophages, as well as
fibroblasts, endothelial cells and cardiomyocytes [39,48,49,50] and
the myocardial tissue of T. cruzi-infected mice [51,52]. Indeed,
treatment of T. cruzi-infected mice with Met-Rantes, a CCL5-
based CCR5 antagonist, reduced the intensity of the inflammatory
heart infiltrate, with little effect on parasitism [52], suggesting that
CCL5-induced migration of CCR5 inflammatory cells may play a
direct role in the genesis of acute T. cruzi-induced myocarditis. A
recent study has shown that Beagle dogs presenting the cardiac
form of T. cruzi infection presented higher myocardial mRNA
expression of CXCL9 and CCL5 than uninfected animals, during
the acute and chronic phases, respectively [53]. Moreover,
microarray analysis have identified genes related to inflammation,
such as chemokines, to be upregulated in myocardium of mice
chronically infected with the Colombian strain of T. cruzi and in
primary murine cardiomyocytes infected with T. cruzi [54,55],
The fact that CXCL9 mRNA expression was the only
chemokine found to display significant correlation with the
intensity of the myocardial infiltrate suggests CXCL9 plays a role
in mononuclear cell migration to CCC myocardium. The
correlation between CXCL9 expression and that of other
chemokines, as well as their CXCR3/CCR5/CCR4/CCR7
receptors (Figure 3 and Supplemental data) may be partially
related to the finding that CXCL9 has immunomodulatory
properties, being able to directly increase expression of CCL2,
CCL3 and CCL4 among other inflammatory genes such as TNF-
a [56]. Expression of all three chemokines has been shown to be
upregulated in CCC myocardial tissue [27], suggesting that
CXCL9 may multiply its T-cell chemoattractant properties with
the aid of CCR5 ligands in CCC heart tissue. It can thus be
hypothesized that IFN-c secreting type 1 T cells in CCC
myocardium induce local production of CXCL9 (and perhaps
CXCL10), which in turn further recruits IFN-c-secreting
CXCR3+/CCR5+ type 1 T cells and other inflammatory cells
directly and indirectly, perpetuating the influx of pathogenic Th1-
type T cells and inflammation.
The polymorphisms CXCL9 rs10336 CC and CXCL10 rs3921
GG, associated with protection from progression to severe CCC,
Figure 4. Chemokine and chemokine receptor expression in
myocardium from patients bearing the CXCL9 and CXCL10 SNPs.
Expression of chemokines and chemokine receptors in myocardium
samples from patients bearing the CXCL9 rs10336 SNP (A). Expression of
chemokines and chemokine receptors in myocardium samples from
patients bearing CXCL10 rs3921 SNP (B). Real-time qPCR analysis of
mRNA levels expression in myocardium samples from patients bearing
the CXCL9 rs10336 CC (n = 5) or CT (n = 9) genotypes (A) and CXCL10
rs3921 GG (n = 5) or CC or CG (n = 9). The bar stands for the median.
doi:10.1371/journal.pntd.0001867.g004
Chemokines in Chagas Cardiomyopathy Myocardium
PLOS Neglected Tropical Diseases | www.plosntds.org 10 October 2012 | Volume 6 | Issue 10 | e1867
are located in the 39UTR region, and the polymorphism CCR5
rs1799988 CC, associated with increased risk for development of
severe CCC, is located at the 59UTR region, where they may
influence binding of gene expression control regions to regulatory
elements. The findings are in line with previous associations of
chemokine or chemokine receptor polymorphisms in CCC
(CCL2 [57], CCL5 [58], CCR5 [29,58]. However, to our
knowledge, is the first study to find gene polymorphisms
associated to the transition to CCC with ventricular dysfunction,
which is the most clinically relevant presentation of disease, the
one associated with significant morbidity and mortality. Previous
gene polymorphism association studies performed in Chagas
disease only disclosed polymorphisms relevant for the transition
between the ASY and the CCC forms, irrespective of clinical
severity (reviewed in [10,59,60,61]. Associations among poly-
morphic variants in the CCR5, CXCL9 and CXCL10 genes and
disease phenotypes have previously been reported. A sequence
variant in the promoter region of the CCR5 gene, which is
associated to reduced expression of CCR5, is associated with
protection to AIDS progression [62] and is also present at a
higher frequency in ASY compared with CCC patients [29].
Although Bruck et al [35] failed to observe any association
between the CXCL9 rs10336 CT polymorphism and type 1
diabetes, the CXCL9 rs2276886 GA polymorphic variant was
associated with a reduced risk for pediatric Crohn’s disease;
significantly, CXCL9 was found to be overexpressed in Crohn’s
disease gut tissue [63]. The CXCL10 -201 G/A polymorphism is
associated with increased susceptibility to chronic hepatitis B
disease progression in males. The CXCL10 -201 G/A is a
functional polymorphism, where allelic variants modulate
CXCL10 expression by differential interaction with CXCL10
transcription factors [64]. Still another CXCL10 polymorphic
variant, CXCL10 rs8878 TT, was found to reduce the risk of type
1 diabetes [65].
Since all our CCC myocardium samples came from clinically
similar end-stage patients submitted to transplantation, it could be
argued that possessing CXCL9 and/or CXCL10 genotypes
associated to reduced myocardial chemokine expression, or even
displaying a less significant inflammatory infiltrate by itself – may
not be relevant for the progression of CCC. However, CCC is not
a monogenic disease, and it is likely that the progression to overt
inflammatory dilated cardiomyopathy may result from the
combined effect and inadequate counterregulation of relevant
genes. Polymorphisms in multiple innate immunity/inflammatory
genes, like IL1b, TNF-a, IL10, IL12, lymphotoxin-a, BAT1,
NFKBIL1, MAL/TIRAP, MIF have been found to associate with
risk for developing CCC (reviewed in [10,59]). In addition to
interference by other genes, differential myocardial resilience,
including responses to hypertrophic/fibrogenic factors occurring
in CCC heart tissue (IL1b, TNF-a, IFN-c, IL18, CCL21), could
explain why these patients carrying the CXCL9/CXCL10 protec-
tive genotypes progressed to end-stage cardiomyopathy. In the
Syrian hamster model of chronic Chagas disease cardiomyopathy,
although the intensity of chronic inflammation correlated with
ventricular dilation, intensity of myocarditis was similar in
hamsters dying from chronic T. cruzi-induced dilated cardiomy-
opathy and survivors euthanized 11 months post-infection [10],
suggesting the existence of additional factors related to death from
CCC.
The finding that the protective CXCL9 rs10336 CC and
CXCL10 rs3921 GG genotypes were associated with lower
myocardial expression of the respective chemokines indicate
either that the polymorphisms are functional themselves or
closely linked to functional polymorphisms. These polymor-
phisms are strongly linked in the caucasian and negroid
populations in the HapMap and test populations (data not
shown). Indeed, the CXCL9 and CXCL10 genes are contained in a
CXC chemokine ‘‘mini-cluster’ at chromosome position 4q21.2
[61,66] and positioned less than 20 Kb apart. The proximity and
linkage of the loci renders it difficult to ascertain which of the two
genes is actually responsible for the immunological effect. In fact,
we found over 60 additional SNPs tightly linked to CXCL9
rs10336 and CXCL10 rs3921 in the reference HapMap/CEPH
CEU (Northern European Caucasian) and YRI (Yoruba, African)
populations in the vicinity of the CXCL9-CXCL10-CXCL11
chemokine minicluster at Chromosome 4. Some of them are at
the 39 UTR or 59UTR regions of either CXCL9 or CXCL10,
with possible transcriptional regulatory activity, and could, in
theory, be responsible for the observed functional association
(Table S9). The fact that samples carrying genotypes associated to
lower risk also displayed reduced expression of several other
chemokines and receptors, as well as with reduced intensity of the
myocardial infiltrate, may suggest that the CXCL9 and CXCL10
genotypes control the intensity of myocarditis through modula-
tion of CXCL9 and/or CXCL10 production and its ensuing
effects on chemokine ligands of the CXCR3/CCR5/CCR4
receptors. Together with the finding of a correlation between
expression of CXCL9 and intensity of myocarditis, these results
suggest that CXCL9 may be a master regulator of chemokine-
driven inflammatory cell migration to CCC heart tissue. Since
the intensity of the infiltrate seems to be a major pathogenic
factor, inflammatory cell recruitment into the myocardium driven
by CXCL9 and other CC and CXC chemokines may play an
important role in the clinical progression to severe, life-
threatening CCC. Several chemokine receptor antagonists are
either on late clinical trials or have been licensed [67,68]. CCR5
and CXCR3 blockers have been shown to suppress migration of
inflammatory cells in acute allograft rejection [69]. Treatment
with Met-Rantes ameliorated acute Chagas disease myocarditis
in murine models [52]. Together with these reports, our results
suggest that the CCR5/CXCR3 receptors may be therapeutic
targets in CCC, where receptor antagonists could dampen
inflammatory T cell migration to myocardium, thus controlling
CCC myocarditis and, possibly, ventricular dysfunction and
death.
Supporting Information
Figure S1 Presence of CD3+, CD4+, CD8+, CCR5+,
CXCR3+, CCR4+, CCL5+ and CXCL9+ cells in heart
tissue. Sections were stained with primary antibodies against
CD3, CD4, CD8, CCR5, CXCR3, CCR4, CCL5 and CXCL9
stained with AF633-labeled (red) and counterstained with DAPI
(blue) as described in Methods.
(TIF)
Figure S2 Correlations between the levels of expression
of different genes in CCC samples. Two-tailed nonpara-
metric correlation of Spearman. ** p,0.01 and * p,0.05.
(TIF)
Figure S3 Correlation between expression profiles of
the 32 studied genes among different CCC myocardial
samples. Two-tailed nonparametric correlation of Spearman.
** p,0.01 and * p,0.05.
(TIF)
Table S1 Characteristics of the primers used in gene
expression analysis.
(DOC)
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Table S2 Characteristics and Minimal Allele Frequency
of tested SNPs.
(DOC)
Table S3 Relative expression values of 14 genes ana-
lyzed in different sites of left ventricular free wall
samples from three CCC patients, CCC-7, CCC-9 and
CCC-10.
(DOC)
Table S4 Genotype and allele frequencies for the CCL4
rs1719153 polymorphism in patients with Chagas dis-
ease. CCC patients were further stratified by left ventricular
ejection fraction values.
(DOC)
Table S5 Genotype and allele frequencies for the CCL5
rs2107538 polymorphism in patients with Chagas dis-
ease. CCC patients were further stratified by left ventricular
ejection fraction values.
(DOC)
Table S6 Genotype and allele frequencies for the
CXCR3 rs2280964 polymorphism in patients with Cha-
gas disease. CCC patients were further stratified by left
ventricular ejection fraction values.
(DOC)
Table S7 Genotype and allele frequencies for the CCL19
rs3136658 polymorphism in patients with Chagas
disease. CCC patients were further stratified by left ventricular
ejection fraction values.
(DOC)
Table S8 Genotype and allele frequencies for the CCL17
rs223827 polymorphism in patients with Chagas dis-
ease. CCC patients were further stratified by left ventricular
ejection fraction values.
(DOC)
Table S9 SNPs in tight linkage disequilibrium with
CXCL9 rs10336 and CXCL10 rs3921.
(DOC)
Acknowledgments
We thank Dr. Priscila Teixeira for helping in heart tissue collection,
Sthefanny Alves for helping in DNA collection, Dr. Ana Lucia Garipo for
providing technical assistance with confocal microscopy, Dr. Maria Lucia
Carnevale Marin and Dr. Lea Campos de Oliveira for helping in SNP
analysis.
Author Contributions
Conceived and designed the experiments: LGN JK ECN. Performed the
experiments: LGN ECM. Analyzed the data: LGN LAB A. Frade ECN.
Contributed reagents/materials/analysis tools: RHBS AIF A. Fragata MS
ED CM BMI EAB NAS MHH BS HLW FD PB. Wrote the paper: LGN
ECN.
References
1. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control.
Trends Parasitol 22: 583–588.
2. Kirchhoff LV, Weiss LM, Wittner M, Tanowitz HB (2004) Parasitic diseases of
the heart. Front Biosci 9: 706–723.
3. Martin UO, Afchain D, de Marteleur A, Ledesma O, Capron A (1987)
[Circulating immune complexes in different developmental stages of Chagas’
disease]. Medicina (B Aires) 47: 159–162.
4. Coura JR (2007) Chagas disease: what is known and what is needed–a
background article. Mem Inst Oswaldo Cruz 102 Suppl 1: 113–122.
5. Higuchi ML, De Morais CF, Pereira Barreto AC, Lopes EA, Stolf N, et al.
(1987) The role of active myocarditis in the development of heart failure in
chronic Chagas’ disease: a study based on endomyocardial biopsies. Clin Cardiol
10: 665–670.
6. Barbosa AP, Cardinalli Neto A, Otaviano AP, Rocha BF, Bestetti RB (2011)
Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated
cardiomyopathy. Arq Bras Cardiol 97: 517–525.
7. Bestetti RB, Muccillo G (1997) Clinical course of Chagas’ heart disease: a
comparison with dilated cardiomyopathy. Int J Cardiol 60: 187–193.
8. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, et al. (2008)
Rationale and design of a randomized placebo-controlled trial assessing the effects
of etiologic treatment in Chagas’ cardiomyopathy: the BENznidazole Evaluation
For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37–43.
9. Milei J, Storino R, Fernandez Alonso G, Beigelman R, Vanzulli S, et al. (1992)
Endomyocardial biopsies in chronic chagasic cardiomyopathy. Immunohisto-
chemical and ultrastructural findings. Cardiology 80: 424–437.
10. Cunha-Neto E, Nogueira LG, Teixeira PC, Ramasawmy R, Drigo SA, et al.
(2009) Immunological and non-immunological effects of cytokines and
chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy.
Mem Inst Oswaldo Cruz 104 Suppl 1: 252–258.
11. Higuchi Mde L, Gutierrez PS, Aiello VD, Palomino S, Bocchi E, et al. (1993)
Immunohistochemical characterization of infiltrating cells in human chronic
chagasic myocarditis: comparison with myocardial rejection process. Virchows
Arch A Pathol Anat Histopathol 423: 157–160.
12. Reis DD, Jones EM, Tostes S Jr, Lopes ER, Gazzinelli G, et al. (1993)
Characterization of inflammatory infiltrates in chronic chagasic myocardial
lesions: presence of tumor necrosis factor-alpha+ cells and dominance of
granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg 48: 637–644.
13. Reis MM, Higuchi Mde L, Benvenuti LA, Aiello VD, Gutierrez PS, et al. (1997)
An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in
chronic human chagasic myocarditis: correlation with the presence of
myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol 83:
165–172.
14. Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, et al. (2001) Chronic
Chagas’ disease cardiomyopathy patients display an increased IFN-gamma
response to Trypanosoma cruzi infection. J Autoimmun 17: 99–107.
15. Morato MJ, Colley DG, Powell MR (1998) Cytokine profiles during
experimental Chagas’ disease. Braz J Med Biol Res 31: 123–125.
16. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, et al. (2000)
Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy:
tissue parasitism and endogenous IFN-gamma as important determinants of
chemokine mRNA expression during infection with Trypanosoma cruzi.
Microbes Infect 2: 851–866.
17. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, et
al. (2003) Evidence that development of severe cardiomyopathy in human
Chagas’ disease is due to a Th1-specific immune response. Infect Immun 71:
1185–1193.
18. Cunha-Neto E, Kalil J (2001) Heart-infiltrating and peripheral T cells in the
pathogenesis of human Chagas’ disease cardiomyopathy. Autoimmunity 34:
187–192.
19. Anez N, Carrasco H, Parada H, Crisante G, Rojas A, et al. (1999) Myocardial
parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 60: 726–
732.
20. Olivares-Villagomez D, McCurley TL, Vnencak-Jones CL, Correa-Oliveira R,
Colley DG, et al. (1998) Polymerase chain reaction amplification of three
different Trypanosoma cruzi DNA sequences from human chagasic cardiac
tissue. Am J Trop Med Hyg 59: 563–570.
21. Fonseca SG, Moins-Teisserenc H, Clave E, Ianni B, Nunes VL, et al. (2005)
Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+
epitopes recognized by T cells from chronically Trypanosoma cruzi-infected
patients. Microbes Infect 7: 688–697.
22. Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, et al. (1996)
Autoimmunity in Chagas’ disease. Identification of cardiac myosin-B13
Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a
chronic Chagas’ cardiomyopathy patient. J Clin Invest 98: 1709–1712.
23. Turner JE, Steinmetz OM, Stahl RA, Panzer U (2007) Targeting of Th1-
associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for
inflammatory diseases. Mini Rev Med Chem 7: 1089–1096.
24. Teixeira MM, Gazzinelli RT, Silva JS (2002) Chemokines, inflammation and
Trypanosoma cruzi infection. Trends Parasitol 18: 262–265.
25. Marino AP, Silva AA, Santos PV, Pinto LM, Gazinelli RT, et al. (2005) CC-
chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-
elicited myocarditis. Mem Inst Oswaldo Cruz 100 Suppl 1: 93–96.
26. Gomes JA, Bahia-Oliveira LM, Rocha MO, Busek SC, Teixeira MM, et al.
(2005) Type 1 chemokine receptor expression in Chagas’ disease correlates with
morbidity in cardiac patients. Infect Immun 73: 7960–7966.
27. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, et al. (2005)
Cardiac gene expression profiling provides evidence for cytokinopathy as a
molecular mechanism in Chagas’ disease cardiomyopathy. Am J Pathol 167:
305–313.
Chemokines in Chagas Cardiomyopathy Myocardium
PLOS Neglected Tropical Diseases | www.plosntds.org 12 October 2012 | Volume 6 | Issue 10 | e1867
28. Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and
antagonistic functions. Immunol Cell Biol 89: 207–215.
29. Calzada JE, Nieto A, Beraun Y, Martin J (2001) Chemokine receptor CCR5
polymorphisms and Chagas’ disease cardiomyopathy. Tissue Antigens 58: 154–
158.
30. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, et al. (2000) Atopic
dermatitis is associated with a functional mutation in the promoter of the C-C
chemokine RANTES. J Immunol 164: 1612–1616.
31. Sekiya T, Tsunemi Y, Miyamasu M, Ohta K, Morita A, et al. (2003) Variations
in the human Th2-specific chemokine TARC gene. Immunogenetics 54: 742–
745.
32. Jorge MT, Macedo TA, Janones RS, Carizzi DP, Heredia RA, et al. (2003)
Types of arrhythmia among cases of American trypanosomiasis, compared with
those in other cardiology patients. Ann Trop Med Parasitol 97: 139–148.
33. Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, et al. (2007)
Locally produced survival cytokines IL-15 and IL-7 may be associated to the
predominance of CD8+ T cells at heart lesions of human chronic Chagas disease
cardiomyopathy. Scand J Immunol 66: 362–371.
34. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE
guidelines: minimum information for publication of quantitative real-time PCR
experiments. Clin Chem 55: 611–622.
35. Bruck P, Bartsch W, Penna-Martinez M, Kahles H, Seidl C, et al. (2009)
Polymorphisms of CXCR3-binding chemokines in type 1 diabetes. Hum
Immunol 70: 552–555.
36. Soto-Sanchez J, Santos-Juanes J, Coto-Segura P, Coto E, Diaz M, et al. (2010)
Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and
psoriatic arthritis. Cytokine 50: 114–116.
37. Zhernakova A, Alizadeh BZ, Eerligh P, Hanifi-Moghaddam P, Schloot NC, et
al. (2006) Genetic variants of RANTES are associated with serum RANTES
level and protection for type 1 diabetes. Genes Immun 7: 544–549.
38. Reis DD, Jones EM, Tostes S, Lopes ER, Chapadeiro E, et al. (1993) Expression
of major histocompatibility complex antigens and adhesion molecules in hearts
of patients with chronic Chagas’ disease. Am J Trop Med Hyg 49: 192–200.
39. Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors
in primary, effector, and memory immune responses. Annu Rev Immunol 18:
593–620.
40. Yates CC, Whaley D, Kulasekeran P, Hancock WW, Lu B, et al. (2007) Delayed
and deficient dermal maturation in mice lacking the CXCR3 ELR-negative
CXC chemokine receptor. Am J Pathol 171: 484–495.
41. Sallusto F, Lanzavecchia A, Mackay CR (1998) Chemokines and chemokine
receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today
19: 568–574.
42. Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, et al. (1998)
Differential expression of chemokine receptors and chemotactic responsiveness
of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129–134.
43. D’Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, et al. (1998)
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon
activation of polarized human type 2 Th cells. J Immunol 161: 5111–5115.
44. Forster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing
immunity and tolerance. Nat Rev Immunol 8: 362–371.
45. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood
fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:
7556–7562.
46. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, et al.
(2005) The chemokine receptor CCR7 activates in dendritic cells two signaling
modules that independently regulate chemotaxis and migratory speed.
J Immunol 174: 4070–4080.
47. Farber JM (1997) Mig and IP-10: CXC chemokines that target lymphocytes.
J Leukoc Biol 61: 246–257.
48. Bujak M, Dobaczewski M, Gonzalez-Quesada C, Xia Y, Leucker T, et al. (2009)
Induction of the CXC chemokine interferon-gamma-inducible protein 10
regulates the reparative response following myocardial infarction. Circ Res 105:
973–983.
49. Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial
chemokine. Trends Immunol 22: 83–87.
50. Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemotactic
cytokines–CXC and CC chemokines. Adv Immunol 55: 97–179.
51. Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ, et al. (2000)
Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines
that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 102:
3003–3008.
52. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, et al. (2004)
Regulated on activation, normal T cell expressed and secreted (RANTES)
antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-
elicited myocarditis. Circulation 110: 1443–1449.
53. Guedes PM, Veloso VM, Talvani A, Diniz LF, Caldas IS, et al. (2010) Increased
type 1 chemokine expression in experimental Chagas disease correlates with
cardiac pathology in beagle dogs. Vet Immunol Immunopathol 138: 106–113.
54. Soares MB, de Lima RS, Rocha LL, Vasconcelos JF, Rogatto SR, et al. (2010)
Gene expression changes associated with myocarditis and fibrosis in hearts of
mice with chronic chagasic cardiomyopathy. J Infect Dis 202: 416–426.
55. Manque PA, Probst CM, Pereira MC, Rampazzo RC, Ozaki LS, et al. (2011)
Trypanosoma cruzi infection induces a global host cell response in cardiomy-
ocytes. Infect Immun 79: 1855–1862.
56. Gong JH, Nicholls EF, Elliott MR, Brown KL, Hokamp K, et al. (2012) G-
protein-coupled receptor independent, immunomodulatory properties of
chemokine CXCL9. Cell Immunol 261: 105–113.
57. Ramasawmy R, Cunha-Neto E, Fae KC, Martello FG, Muller NG, et al. (2006)
The monocyte chemoattractant protein-1 gene polymorphism is associated with
cardiomyopathy in human chagas disease. Clin Infect Dis 43: 305–311.
58. Florez O, Martin J, Gonzalez CI (2012) Genetic variants in the chemokines and
chemokine receptors in Chagas disease. Hum Immunol.
59. Bilate AM, Cunha-Neto E (2008) Chagas disease cardiomyopathy: current
concepts of an old disease. Rev Inst Med Trop Sao Paulo 50: 67–74.
60. Drigo SA, Cunha-Neto E, Ianni B, Cardoso MR, Braga PE, et al. (2006) TNF
gene polymorphisms are associated with reduced survival in severe Chagas’
disease cardiomyopathy patients. Microbes Infect 8: 598–603.
61. Lee HH, Farber JM (1996) Localization of the gene for the human MIG
cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine ‘‘mini-
cluster’’. Cytogenet Cell Genet 74: 255–258.
62. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, et
al. (1998) CCR5 promoter polymorphism and HIV-1 disease progression.
Multicenter AIDS Cohort Study (MACS). Lancet 352: 866–870.
63. Lacher M, Kappler R, Berkholz S, Baurecht H, von Schweinitz D, et al. (2007)
Association of a CXCL9 polymorphism with pediatric Crohn’s disease. Biochem
Biophys Res Commun 363: 701–707.
64. Deng G, Zhou G, Zhang R, Zhai Y, Zhao W, et al. (2008) Regulatory
polymorphisms in the promoter of CXCL10 gene and disease progression in
male hepatitis B virus carriers. Gastroenterology 134: 716–726.
65. Klich I, Fendler W, Wyka K, Mlynarski W (2011) Effect of the IP10 (CXCL10)
and HLA genotype on the risk of type 1 diabetes in children. Pediatr Endocrinol
Diabetes Metab 17: 10–13.
66. Erdel M, Theurl M, Meyer M, Duba HC, Utermann G, et al. (2001) High-
resolution mapping of the human 4q21 and the mouse 5E3 SCYB chemokine
cluster by fiber-fluorescence in situ hybridization. Immunogenetics 53: 611–615.
67. Troia-Cancio P, Asmuth DM (2011) Lessons from maraviroc clinical trials.
Expert Rev Anti Infect Ther 9: 649–651.
68. Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, et al. (2010) Homing of
immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel
Dis 16: 1969–1977.
69. Kakuta Y, Okumi M, Miyagawa S, Tsutahara K, Abe T, et al. (2012) Blocking
of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal
allograft rejection. Transplantation 93: 24–31.
Chemokines in Chagas Cardiomyopathy Myocardium
PLOS Neglected Tropical Diseases | www.plosntds.org 13 October 2012 | Volume 6 | Issue 10 | e1867
